Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Merck Expects To Lose $200 Million on Tariffs in 2025
Posted
April 24, 2025
Views
708
Likes
6
Engagement
0.85%
April 24, 2025
708
6
0.85%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
5:44Now PlayingMerck expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China.
The company's first-quarter results beat estimates, with sales of $15.5 billion and adjusted earnings of $2.22 per share.
Merck expects to launch an easier-to-use version of Keytruda later this year and is counting on new medicines to offset the impending decline of Keytruda.
Merck's sales of Gardasil vaccine have fallen 41% in the first quarter, but the company is counting on new medicines, including a easier-to-use version of Keytruda, to offset the decline.
Bloomberg's Damian Garde reports.
--------
Get more on The Bloomberg Intelligence Podcast
Follow us on X
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
